
The Phase 2 study missed its primary and secondary endpoints, while Aclaris said the drug was generally well tolerated.
Aclaris Therapeutics said its Phase 2 ADMIRATION trial of bosakitug in moderate-to-severe atopic dermatitis missed its primary and secondary endpoints. The primary measure was the percent change in EASI score from baseline at Week 24.
The company said bosakitug was generally well tolerated. Pharmacodynamic results showed TSLP target engagement and lower levels of biomarkers related to Th1, Th2 and Th17 immune activation.
Aclaris said the results do not change its priorities, which include oral kinase inhibitors and its anti-TSLP/IL-4Rα bispecific antibody ATI-052. The company said it has initiated a Phase 2b trial of modzatinib for lichen planus and intends to start a Phase 2b ATI-052 trial in eosinophilic esophagitis in the first quarter of 2027.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.